新型探针[123I]I-PSMA-7用于前列腺癌实时术中靶向活检与SPECT/CT成像的首次人体临床前评估
本研究合成高亲和力探针[123I]I-PSMA-7,纳入10例疑似前列腺癌患者分两组行注射与活检间隔约24小时的活检,另入组3例评估其检测前列腺癌的潜力。注射185MBq后55条活检芯中18条阳性,阳性芯cpm显著高于阴性芯(4345±3547 vs 714±547,P<0.001),AUC 0.97,cutoff 1312,灵敏度/特异度94.40%/91.90%。
要点
- 注射185MBq [123I]I-PSMA-7后,阳性活检芯cpm显著高于阴性芯(4345±3547 vs 714±547,P<0.001)。
- 该剂量下AUC 0.97,cutoff 1312,灵敏度94.40%、特异度91.90%。
- 低剂量下阳性芯cpm为2446±1622 vs 阴性芯153±112(P<0.001),AUC为1,cutoff 490,灵敏度100%。
核心结论
- 借助[123I]I-PSMA-7并通过基于cpm的活检,可将活检次数降至最低操作。
- [123I]I-PSMA-7 PSMA SPECT/CT也可提供良好的成像结果。
研究设计与样本
- 研究合成高亲和力探针[123I]I-PSMA-7并评估其性质,先行动物实验验证安全性、靶向性与有效性。
- 纳入10例疑似前列腺癌患者并分为两组,注射与活检间隔约24小时,用γ计数器测量活检病灶的cpm。
- 另入组3例患者评估[123I]I-PSMA-7检测前列腺癌的潜力。
主要发现
- 动物实验验证了[123I]I-PSMA-7的安全性、靶向性与有效性,肿瘤/肌肉比值在24小时最大,并证实了本研究在人体中的结果。
- 注射185MBq [123I]I-PSMA-7后,55条活检芯中18条阳性,阳性芯cpm显著大于阴性芯(4345±3547 vs 714±547,P<0.001),AUC为0.97,cutoff为1312,灵敏度/特异度为94.40%/91.90%。
- 较低剂量下55条活检芯中10条为癌,阳性芯cpm为2446±1622 vs 阴性芯153±112(P<0.001),AUC为1,cutoff值为490,灵敏度/特异度为100%。
- 当放射性药物加至370MBq时,获得了更好的SPECT/CT成像。
关键数值与推荐
- 注射185MBq [123I]I-PSMA-7后行活检,以cpm cutoff 1312判别阳性芯,灵敏度94.40%、特异度91.90%,AUC 0.97。
- 较低剂量下以cpm cutoff 490判别阳性芯,灵敏度100%,AUC为1。
- 放射性药物加至370MBq时可获得更好的SPECT/CT成像。
临床怎么用
- 作者认为,借助[123I]I-PSMA-7并通过基于cpm的活检,可将活检次数降至最低操作。
- 作者认为,[123I]I-PSMA-7 PSMA SPECT/CT可提供良好的成像结果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: PSMA/PET has been increasingly used to detect PCa, and PSMA/PET-guided biopsy has shown promising results. However, it cannot be confirmed immediately whether the tissues are the targeted area. In this study, we aimed to develop a novel probe, [123I]I-PSMA-7. First, we hope that [123I]I-PSMA-7 can provide instant confirmation for prostate biopsy. Second, we hope it will help detect PCa. METHODS: We synthesized a high-affinity probe, [123I]I-PSMA-7, and evaluated its properties. We included ten patients with suspected PCa and divided them into two groups. The injection and biopsy were approximately 24 h apart. The activity in biopsy lesions was measured as the cpm by a γ-counter. Moreover, we enrolled 3 patients to evaluate the potential of [123I]I-PSMA-7 for detecting PCa. RESULTS: Animal experiments verified the safety, targeting and effectiveness of [123I]I-PSMA-7, and the tumor-to-muscle ratio was greatest at 24 h, which confirmed the results of this study in humans. After injection of 185MBq [123I]I-PSMA-7, 18/55 cores were positive, and the cpm was significantly greater (4345 ± 3547 vs. 714 ± 547, P < 0.001), with an AUC of 0.97 and a cutoff of 1312 (sens/spec of 94.40%/91.90%). At a lower dose, 10/55 biopsy cores were cancerous, and the cpm was 2446 ± 1622 vs. 153 ± 112 (P < 0.001). The AUC was 1, with a cutoff value of 490 (sens/spec of 100%). When the radiopharmaceuticals were added to 370 MBq, we achieved better SPECT/CT imaging. CONCLUSION: With the aid of [123I]I-PSMA-7 and via cpm-based biopsy, we can reduce the number of biopsies to a minimum operation. [123I]I-PSMA-7 PSMA SPECT/CT can also provide good imaging results. TRIAL REGISTRATION: Chinese Clinical trial registry ChiCTR2300069745, Registered 24 March 2023.
引用
- Luan X, Niu S, Liu Y, et al. The first-in-human preclinical evaluation of the new probe [123I]I-PSMA-7 for real-time intraoperative targeted biopsy and SPECT/CT imaging in prostate cancer. Eur J Nucl Med Mol Imaging. 2024. PMID: 39042333. doi:10.1007/s00259-024-06833-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。